Max Healthcare, Apollo Hospitals, Sun Pharma, Dr Reddy’s: Stocks in focus as NPPA caps cancer drug margins

Shares of hospital chains and pharmaceutical companies with oncology exposure will be in focus on Monday, October 19, after the National Pharmaceutical Pricing Authority (NPPA) capped trade margins at 30% for 137 identified non-scheduled anti-cancer drug formulations.

The measure, effective November 9, 2026, is expected to reduce the maximum retail prices (MRPs) of the affected medicines by up to 70%, depending on their existing price structures. The move aims to curb excessive margins in the distribution chain and make cancer treatment more affordable.

Identified non-scheduled anti-cancer drugs are a specific list of cancer medicines selected by the government for the new pricing measure.

What is a trade margin?

Trade margins refer to the difference between the price at which a distributor or retailer buys a medicine and the price at which it sells it, before accounting for operating expenses.

In simple terms, it is the amount that distributors and retailers earn on the sale of a drug.

By capping trade margins at 30%, the NPPA aims to limit how much intermediaries can add to the price of the identified anti-cancer medicines, making them more affordable for patients.

Key details of the NPPA move

The list of 137 formulations includes immunotherapy drugs used to treat multiple types of cancer, as well as medicines such as denosumab, pegfilgrastim and bevacizumab. It also covers widely used anti-cancer drugs such as pembrolizumab, durvalumab and osimertinib.

The NPPA has invoked Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, to implement trade margin rationalisation (TMR). Manufacturers must notify the regulator of revised prices within seven days of the Gazette notification. Hospitals, retailers and other sellers will be required to charge the revised prices from November 9.

The move expands on the regulator’s 2019 initiative, under which trade margins on 42 anti-cancer drugs were capped at 30%, resulting in price reductions for hundreds of medicine brands.

Stocks in focus: How could they be impacted?

However, the overall impact on these hospital chains will depend on their exposure to the 137 formulations, procurement costs, and the contribution of medicine sales to their oncology business.

Lower drug prices could also improve affordability and access to treatment, potentially benefiting patient volumes over time.

The net impact on revenue and margins remains uncertain.

The impact will depend on which of their medicines are covered and the extent to which the revised pricing norms affect their sales and distribution arrangements.

The 30% cap applies to trade margins and does not automatically translate into an equivalent reduction in manufacturers’ realisations or profits.

Therefore, the impact on their earnings cannot be determined without assessing their product-level exposure.

While hospital and pharmaceutical stocks may react to the announcement, the actual impact on earnings will depend on the affected products’ contribution to their businesses, analysts explain.